Nervio – an advanced eHealth Ventures company – is growing in team, funds and clinical network !
We are happy to announce more success from Nervio, an eHV portfolio company focused on an autonomous neuromonitoring – an AI solution to prevent permanent damage caused during unmonitored neurosurgeries.
Nervio is proud to introduce Mr. Ariel Weinstein as its new CEO : Ariel is a highly experienced and business-oriented executive who is joining Nervio’s management team. Ariel will join Nir Zarchi, the company’s co-founder, as the new CEO. Ariel brings over 20 years of experience as a prominent executive in the fields of Medical Devices and Digital Health, with proven achievements and success in commercial launches and building up sales channels. Nir will assume the role of Chief Product & Innovation Officer.
In addition, and following a successful round of financing (by eHV and other investors), Nervio is expanding its clinical trial program in the US – and is about to start another trial at St. Mary’s Hospital in Philadelphia, part of the Trinity Network.
For more information: ariel@nervio.ai or izik.i@nervio.ai
About eHealth Ventures
The eHealth Ventures partnership is a leading investor in early-stage digital health companies.
It includes 2 VC funds and a technological incubator with an exclusive focus on digital health and significant government non-dilutive funding. Partners include Maccabi (a leading Israeli HMO), Amgen (global biotech giant), the Mayo Clinic, Medison Ventures, Arad Investments, and the Hadar Group. The team has reviewed over 1,650 companies to date and invested in a portfolio of 24 highly innovative companies (digital diagnostics, therapeutics, home care and Bioconvergence).
